BACKGROUND: Posterior reversible encephalopathy syndrome (PRES) comprises clinical and radiologic findings with rapid onset and potentially dire consequences. Patients experience hypertension, seizures, headache, visual disturbance, and/or altered mentation. Magnetic resonance imaging reveals edematous changes in the brain (especially in the parietal and occipital lobes). In this report, the authors describe PRES associated with antidisialoganglioside (anti-GD2 ) monoclonal antibody (MoAb) immunotherapy, which is now standard for high-risk neuroblastoma but has not previously been implicated in PRES. METHODS: Successive clinical trials using the anti-GD2 MoAb 3F8 (a murine immunoglobulin 3 MoAb specific for GD2) for patients with neuroblastoma involved multiple cycles of standard-dose 3F8 (SD-3F8) (20 mg/m2 daily for 5 days per cycle) or 2 cycles of high-dose 3F8 (HD-3F8) (80 mg/m2 daily for 5 days per cycle) followed by cycles of SD-3F8. RESULTS: PRES was diagnosed in 5 of 215 patients (2.3%), including 3 of 160 (1.9%) who received SD-3F8 and 2 of 55 (3.6%) who received HD-3F8 (P = .6). All 5 patients had a rapid return to clinical-radiologic baseline. PRES occurred in 3 of 26 patients (11.5%) whose prior treatment included external-beam radiotherapy to the brain (2 of 6 patients status-post total body irradiation and 1 of 20 patients status-post craniospinal irradiation) compared with 2 of 189 patients (1.1%) who had not received prior brain irradiation (P = .01). Hypertension, which is strongly linked to PRES, reached grade 3 toxicity in 12 of 215 patients (5.6%), including the 5 patients with PRES and 7 patients without PRES. CONCLUSIONS: Patients who receive anti-GD2 MoAb immunotherapy should be closely monitored for, and undergo urgent treatment or evaluation of, symptoms that may herald PRES (eg, hypertension or headaches). Prior brain irradiation may be a predisposing factor for PRES with this immunotherapy.
BACKGROUND: Posterior reversible encephalopathy syndrome (PRES) comprises clinical and radiologic findings with rapid onset and potentially dire consequences. Patients experience hypertension, seizures, headache, visual disturbance, and/or altered mentation. Magnetic resonance imaging reveals edematous changes in the brain (especially in the parietal and occipital lobes). In this report, the authors describe PRES associated with antidisialoganglioside (anti-GD2 ) monoclonal antibody (MoAb) immunotherapy, which is now standard for high-risk neuroblastoma but has not previously been implicated in PRES. METHODS: Successive clinical trials using the anti-GD2 MoAb3F8 (a murine immunoglobulin 3 MoAb specific for GD2) for patients with neuroblastoma involved multiple cycles of standard-dose 3F8 (SD-3F8) (20 mg/m2 daily for 5 days per cycle) or 2 cycles of high-dose 3F8 (HD-3F8) (80 mg/m2 daily for 5 days per cycle) followed by cycles of SD-3F8. RESULTS: PRES was diagnosed in 5 of 215 patients (2.3%), including 3 of 160 (1.9%) who received SD-3F8 and 2 of 55 (3.6%) who received HD-3F8 (P = .6). All 5 patients had a rapid return to clinical-radiologic baseline. PRES occurred in 3 of 26 patients (11.5%) whose prior treatment included external-beam radiotherapy to the brain (2 of 6 patients status-post total body irradiation and 1 of 20 patients status-post craniospinal irradiation) compared with 2 of 189 patients (1.1%) who had not received prior brain irradiation (P = .01). Hypertension, which is strongly linked to PRES, reached grade 3 toxicity in 12 of 215 patients (5.6%), including the 5 patients with PRES and 7 patients without PRES. CONCLUSIONS:Patients who receive anti-GD2 MoAb immunotherapy should be closely monitored for, and undergo urgent treatment or evaluation of, symptoms that may herald PRES (eg, hypertension or headaches). Prior brain irradiation may be a predisposing factor for PRES with this immunotherapy.
Authors: Nai-Kong V Cheung; Rebecca Sowers; Andrew J Vickers; Irene Y Cheung; Brian H Kushner; Richard Gorlick Journal: J Clin Oncol Date: 2006-05-08 Impact factor: 44.544
Authors: T Simon; B Hero; A Faldum; R Handgretinger; M Schrappe; D Niethammer; F Berthold Journal: Klin Padiatr Date: 2005 May-Jun Impact factor: 1.349
Authors: K K Matthay; J G Villablanca; R C Seeger; D O Stram; R E Harris; N K Ramsay; P Swift; H Shimada; C T Black; G M Brodeur; R B Gerbing; C P Reynolds Journal: N Engl J Med Date: 1999-10-14 Impact factor: 91.245
Authors: David M King; Mark R Albertini; Heidi Schalch; Jacquelyn A Hank; Jacek Gan; Jean Surfus; David Mahvi; Joan H Schiller; Thomas Warner; KyungMann Kim; Jens Eickhoff; Kari Kendra; Ralph Reisfeld; Stephen D Gillies; Paul Sondel Journal: J Clin Oncol Date: 2004-10-13 Impact factor: 44.544
Authors: T N Trahair; M R Vowels; K Johnston; R J Cohn; S J Russell; K A Neville; S Carroll; G M Marshall Journal: Bone Marrow Transplant Date: 2007-08-27 Impact factor: 5.483
Authors: Kaci L Osenga; Jacquelyn A Hank; Mark R Albertini; Jacek Gan; Adam G Sternberg; Jens Eickhoff; Robert C Seeger; Katherine K Matthay; C Patrick Reynolds; Clare Twist; Mark Krailo; Peter C Adamson; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel Journal: Clin Cancer Res Date: 2006-03-15 Impact factor: 12.531
Authors: M R Albertini; J A Hank; J H Schiller; M Khorsand; A A Borchert; J Gan; R Bechhofer; B Storer; R A Reisfeld; P M Sondel Journal: Clin Cancer Res Date: 1997-08 Impact factor: 12.531
Authors: Thomas H Beckham; Dana L Casey; Michael P LaQuaglia; Brian H Kushner; Shakeel Modak; Suzanne L Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2017-04-11 Impact factor: 7.038
Authors: Aleksandra Wieczorek; Carla Manzitti; Alberto Garaventa; Juliet Gray; Vassilios Papadakis; Dominique Valteau-Couanet; Katarzyna Zachwieja; Ulrike Poetschger; Ingrid Pribill; Stefan Fiedler; Ruth Ladenstein; Holger N Lode Journal: Cancers (Basel) Date: 2022-04-10 Impact factor: 6.575
Authors: Jose L Daniotti; Aldo A Vilcaes; Vanina Torres Demichelis; Fernando M Ruggiero; Macarena Rodriguez-Walker Journal: Front Oncol Date: 2013-12-19 Impact factor: 6.244
Authors: Atif Zafar; Wei Wang; Gang Liu; Xinjie Wang; Wa Xian; Frank McKeon; Jennifer Foster; Jia Zhou; Ruiwen Zhang Journal: Med Res Rev Date: 2020-11-06 Impact factor: 12.944
Authors: Scott J Morin; Chinmay Jani; Arashdeep Rupal; Harpreet Singh; Daniel Bourque; Robert C Colgrove Journal: Am J Ther Date: 2021-07-05 Impact factor: 3.098